Expert Update on Lp(a): Dr Patrick Moriarty Explains the Next CVD Target

October 21, 2020

Elevated lipoprotein A is a genetically determined independent risk factor for CVD, affecting up to 30% of the population. Phase 3 trials for the first treatment are underway.

________________________________________________________________
Patrick M Moriarty, MD, is professor of medicine and director of clinical pharmacology and the Atherosclerosis/Lipoprotein-Apheresis Center at the University of Kansas Medical Center, in Kansas City.

His research activities include atherosclerosis, lipid apheresis, vascular inflamation and hemorheology. He has participated in numerous clinical trials related to dyslipidemia, obesity, hypertension, and diabetes. His clinical activities involve the treatment and diagnosis of atherosclerosis and cardiovascular disease.

Expert Update on Lp(a): Dr Patrick Moriarty Explains the Next CVD Target

________________________________________________________________Patrick M Moriarty, MD, is professor of medicine and director of clinical pharmacology and the Atherosclerosis/Lipoprotein-Apheresis Center at the University of Kansas Medical Center, in Kansas City.

________________________________________________________________
Patrick M Moriarty, MD, is professor of medicine and director of clinical pharmacology and the Atherosclerosis/Lipoprotein-Apheresis Center at the University of Kansas Medical Center, in Kansas City.